trending Market Intelligence /marketintelligence/en/news-insights/trending/3hmal2os5egcusdker0e8q2 content esgSubNav
In This List

Intellipharmaceutics closes $1.8M direct offering of common stock


Japan M&A By the Numbers: Q4 2023


Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise

Intellipharmaceutics closes $1.8M direct offering of common stock

Intellipharmaceutics International Inc. closed its registered direct offering of 3 million common shares priced at 60 cents apiece with gross proceeds of about $1.8 million.

The company also issued to the investors unregistered warrants to buy 1.5 million shares at an exercise price of 60 cents apiece.

Intellipharmaceutics raised about $1.5 million in net proceeds through this offering.

The company plans to use the net proceeds for general corporate purposes, which may include working capital, capital expenditures, research and development, accounts payable and other commercial expenditures.

H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.

Intellipharmaceutics recently raised $3.5 million through a separate offering that closed March 16.

Toronto-based Intellipharmaceutics International is a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled- and targeted-release oral solid dosage drugs.